Sign up to save your data!
Some tips to help get started:
Processing...
There are 746 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.
746 trials meet filter criteria.
Sort by:
HealthScout AI summary: Adults with advanced or metastatic non-small cell lung cancer harboring EGFR activating mutations who have progressed on or are ineligible for standard EGFR-TKI therapies (including cases with resistance mutations like C797S) may enroll to receive BG-60366, an oral chimeric degradation activation compound that selectively degrades mutant EGFR. Prior small cell transformation, symptomatic CNS metastases, previous fourth-generation EGFR-TKIs, and significant interstitial lung disease are exclusion criteria.
ClinicalTrials.gov ID: NCT06685718
HealthScout AI summary: Adults with advanced or metastatic solid tumors (including NSCLC, triple-negative breast cancer, head and neck squamous cell carcinoma, gastric cancer, or melanoma), particularly those refractory or relapsed after immune checkpoint inhibitors, will receive the investigational anti-CCR8 monoclonal antibody BAY3375968 (which depletes tumor-infiltrating Tregs) as monotherapy or combined with pembrolizumab. Eligible patients must have measurable disease, ECOG 0-1, and be willing to undergo tumor biopsies.
ClinicalTrials.gov ID: NCT05537740
HealthScout AI summary: This trial enrolls adults with advanced or metastatic GPC3-expressing solid tumors (including hepatocellular carcinoma, AFP-producing gastric cancer, extragonadal yolk sac tumors, non-dysgerminomas, or GPC3-positive squamous NSCLC) who have ECOG 0-1. Patients will receive the investigational bispecific antibody BGB-B2033 (targeting GPC3 and 4-1BB) alone or combined with the anti-PD-1 antibody tislelizumab.
ClinicalTrials.gov ID: NCT06427941
HealthScout AI summary: This trial enrolls adults with recurrent, unresectable, locally advanced, or metastatic solid tumors—including colorectal, pancreatic, NSCLC, ovarian cancer, mesothelioma, and others—that express mesothelin (MSLN) and have lost HLA-A*02 expression, who are heterozygous for HLA-A*02. Eligible patients receive a single infusion of A2B694, an autologous CAR T-cell therapy engineered with a logic-gated Tmod system to selectively target MSLN-positive, HLA-A*02-negative tumor cells.
ClinicalTrials.gov ID: NCT06051695
HealthScout AI summary: Eligible patients are adults with metastatic or advanced solid tumors—including breast, non-small cell lung (EGFR-mutant or wild-type), gastric, gastroesophageal, or colorectal cancer—who have progressed on, are intolerant to, or lack access to standard therapies. The investigational treatment is DM001, a bispecific antibody-drug conjugate targeting TROP2 and EGFR and delivering a topoisomerase I inhibitor, administered intravenously every 21 days.
ClinicalTrials.gov ID: NCT06475937
HealthScout AI summary: This study enrolls adults with locally advanced unresectable or metastatic solid tumors harboring KRAS G12C mutations who have progressed on or are intolerant to standard therapy, to receive oral FMC-376, a novel dual inhibitor of both active and inactive KRAS G12C. Eligible patients must have ECOG 0-1.
ClinicalTrials.gov ID: NCT06244771
HealthScout AI summary: This trial enrolls adults with advanced solid tumors (including NSCLC, colorectal, breast, ovarian, renal, head and neck, and urothelial carcinomas) who have progressed on or are intolerant to standard therapies, with a dose expansion cohort for advanced non-squamous NSCLC negative for common actionable mutations and previously treated with platinum chemotherapy plus PD-(L)-1 inhibitors. Patients receive AB801, an oral selective AXL inhibitor, as monotherapy or in combination with docetaxel.
ClinicalTrials.gov ID: NCT06120075
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring any SMARCA4 mutation who have progressed on, or are ineligible for, standard therapies, and treats them with PRT7732, a first-in-class oral degrader selectively targeting the SMARCA2 protein. Patients with co-occurring SMARCA2 mutations are excluded.
ClinicalTrials.gov ID: NCT06560645
HealthScout AI summary: This trial enrolls adults with metastatic, measurable solid tumors (including GI, GU, breast, ovarian, endocrine tumors, NSCLC, and multiple myeloma with plasmacytomas) who have progressed after standard therapies, and treats them with autologous T-cells genetically engineered to express T-cell receptors targeting patient-specific tumor neoantigens, following lymphodepletion, with or without the addition of pembrolizumab. The investigational TCR therapy directly targets mutated or viral antigens unique to each patient’s cancer in an effort to induce durable tumor regression.
ClinicalTrials.gov ID: NCT03412877
HealthScout AI summary: This trial enrolls adults with unresectable, recurrent, or metastatic solid tumors (including dedicated cohorts for melanoma post anti-PD-1 therapy and platinum-resistant ovarian cancer) to receive DF6215—a novel, half-life extended monovalent IL-2 agonist designed to selectively activate CD8+ T cells and NK cells—either alone or in combination with pembrolizumab. Participants must have ECOG 0-1, adequate organ function, and meet strict cardiac and infection criteria.
ClinicalTrials.gov ID: NCT06108479
